QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
07. Februar 2024 16:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the...
Telix Radiopharmaceutical Production Facility Buildout Commences
21. März 2022 18:41 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development...
EAU Updates Guidance for PSMA-PET Imaging
21. März 2022 01:28 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the updated 2022 ‘Guidelines on Prostate...
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
07. März 2022 17:37 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,...
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
15. Februar 2022 17:39 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a commercial distribution agreement with...
Telix and SHINE partner for Lutetium-177 Supply
10. Februar 2022 16:09 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
08. Februar 2022 17:27 ET
|
Telix Pharmaceuticals Limited
MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a global clinical supply agreement with Berlin-based...
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
07. Februar 2022 18:08 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
27. Januar 2022 16:41 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
26. Januar 2022 16:51 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s...